Highest-materiality recent filing
AbCellera announces $56M upfront collaboration with Jazz Pharma for T-cell engager antibodies
$56M upfront for first two programs; $28M additional upon initiation of third program within 12 months.
AbCellera reports Q1 net loss $43.2M; positive Phase 1 data for ABCL635 supports monthly dosing
Net loss of $43.2M ($0.14 loss per share) vs $45.6M loss in Q1 2025; revenue $8.3M up from $4.2M.
AbCellera FY2025 revenue $75.1M, net loss $146.4M; liquidity ~$700M
Revenue $75.1M vs $28.8M YoY; net loss $146.4M vs $162.9M; EPS $(0.49) vs $(0.55).
AbCellera settles Bruker patent litigation; $36M upfront plus ongoing royalties
Bruker to pay AbCellera $36 million upfront as part of global patent settlement.
AbCellera Q3 net loss widens to $57.1M; revenue rises to $9.0M
Net loss of $57.1M ($0.19/share) vs $51.1M ($0.17/share) in Q3 2024.
AbCellera reports Q2 net loss $34.7M, revenue up 134% YoY; starts Phase 1 for VMS drug ABCL635
Revenue $17.1M vs $7.3M YoY (134% increase); net loss $34.7M ($0.12 loss per share) vs $36.9M ($0.13) prior year.
AbCellera receives Health Canada authorization for Phase 1 trial of ABCL575 for atopic dermatitis
Health Canada issued No Objection Letter authorizing Clinical Trial Application for ABCL575, an anti-OX40L antibody.
CAFC affirms validity of AbCellera's microfluidic cell culture patent against Bruker challenge
Federal Circuit affirms PTAB decision upholding all claims of U.S. Patent No. 10,087,408.
AbCellera Q1 revenue down 58% to $4.2M; net loss $45.6M; introduces ABCL635 for hot flashes
Total revenue $4.2M, down 58% from $10.0M in Q1 2024.
Revenue $28.8M vs $38.0M in 2023; net loss $162.9M ($0.55 loss per share) vs $146.4M loss in 2023.
AbCellera Q3 net loss widens to $51.1M as expenses rise; revenue flat at $6.5M
Revenue $6.5M, flat QoQ and YoY; net loss $51.1M ($0.17/share) vs $28.6M ($0.10/share) in Q3 2023.
AbCellera Q2 net loss $36.9M, revenue down 28% YoY; Lilly collaboration expanded
Net loss $36.9M ($0.13/sh) vs $30.5M loss in Q2 2023; revenue $7.3M down from $10.1M.
AbCellera FY2023 revenue $38M (down 92% YoY), net loss $0.51/share
Revenue fell to $38.0M from $485.4M in FY2022; research fees were $35.6M.
AbCellera cuts ~10% of workforce in reorganization; estimates $2.5M cash cost
Reduction impacts approximately 10% of employees to focus on clinical development and strategic partnerships.
AbCellera Q3 revenue plunges to $6.6M from $101M; net loss $0.10/sh vs prior year profit
Total revenue $6.6M, down 93.5% from $101.4M in Q3 2022.
AbCellera Q2 revenue drops 78% to $10M; net loss widens to $0.11/share
Total revenue $10.1M vs $45.9M in Q2 2022; research fees fell to $9.8M from $12.5M.
AbCellera enters $701M co-investment with Canadian, BC governments for antibody drug development
CA$701M co-investment: AbCellera invests CA$401M, Canada CA$225M, BC CA$75M over 8 years.
AbCellera Q1 2023 revenue $12M, net loss $0.14 EPS vs $0.59 EPS profit in Q1 2022
Total revenue $12.2M, down from $316.6M in Q1 2022; net loss $40.1M vs net income $168.6M.
AbCellera FY2022 revenue $485M, net income $158.5M; 23 new partnered programs started
Total revenue $485.4M (up 29% YoY); net income $158.5M ($0.50 diluted EPS) vs $153.5M ($0.48 diluted) in 2021.
AbCellera Q3 revenue $101.4M, net income $0.09/share; program starts up 33%
Total revenue $101.4M (Q3 2021: $5.5M); net income $26.6M ($0.09 basic EPS) vs net loss $21.4M.
AbCellera Q2 2022 revenue rises to $46M, net loss widens to $7M; 4 new program starts
Total revenue $45.9M, up 66% from $27.6M in Q2 2021; royalties from bebtelovimab contributed $33.2M.
AbCellera loses Chief Business Officer Neil Berkley effective June 29, 2022
Neil Berkley departed as Chief Business Officer effective June 29, 2022; not due to any disagreement with the Company.
Lilly to supply additional 150K doses of AbCellera's bebtelovimab for ~$275M
Eli Lilly modified agreement with U.S. government for 150,000 additional doses of bebtelovimab at ~$275M.
AbCellera Q1 2022 revenue $317M, net earnings $0.59/sh, up from $0.43/sh YoY
Total revenue $316.6M (up 56% YoY from $202.7M); net earnings $168.6M ($0.59 basic EPS vs $0.43).
AbCellera FY2021 revenue $375M (+61% YoY); EPS $0.56; 26 new program starts
Total revenue $375.2M (up 61% from $233.2M in 2020), driven by $327.3M in royalty revenue.
AbCellera-discovered antibody bebtelovimab receives FDA EUA for COVID-19 treatment
Bebtelovimab (LY-CoV1404) authorized for mild-to-moderate COVID-19 in high-risk patients 12+.
AbCellera Q3 net loss $21.4M ($0.08/share); revenue falls to $5.5M from $9.4M
Total revenue $5.5M, down 41% from $9.4M in Q3 2020 due to lower milestone payments and bamlanivimab royalty pause.
AbCellera announces U.S. government purchase of 614,000 doses of bamlanivimab/etesevimab for $1.29B
Lilly will supply 614,000 additional doses no later than January 31, 2022; minimum 400,000 by December 31, 2021.
AbCellera: EU Joint Procurement for up to 220,000 doses of bamlanivimab/etesevimab
EC and Lilly agree to supply up to 220,000 doses of bamlanivimab plus etesevimab for COVID-19 in EU/EEA patients 12+ at risk.
On June 30, 2026, the Board of Directors (the "Board") of AbCellera Biologics Inc. (the "Company") appointed Lynn Seely, M.D as a new Class III director.
On June 1, 2026, the Board of Directors (the "Board") of AbCellera Biologics Inc. (the "Company") appointed Victor Sandor as a new director.
On February 16, 2024, Peter Thiel, a member of the Board of Directors of AbCellera Biologics Inc. (the “Company”) and the Chairman of the Nominating and Corporate Governance Committee thereof, notified the Company of his intention to retire from the Company’s Board of Directors and all committees for personal reasons, effective March 7, 2024.
the departure of Neil Berkley, its Chief Business Officer, from the Company effective June 29, 2022.
Effective June 29, 2022, Neil Berkley is no longer the Chief Business Officer of AbCellera Biologics Inc.
Max materiality 0.85 · Median 0.60 · Most common event earnings